|
PE20090717A1
(es)
*
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
TW200911798A
(en)
|
2007-08-02 |
2009-03-16 |
Amgen Inc |
PI3 kinase modulators and methods of use
|
|
EP2211615A4
(en)
*
|
2007-10-22 |
2010-10-13 |
Glaxosmithkline Llc |
PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
|
|
AU2008343813B2
(en)
|
2007-12-19 |
2012-04-12 |
Amgen Inc. |
Inhibitors of PI3 kinase
|
|
CA2725014C
(en)
|
2008-05-30 |
2014-06-17 |
Amgen Inc. |
Inhibitors of pi3 kinase
|
|
JPWO2009157196A1
(ja)
*
|
2008-06-25 |
2011-12-08 |
武田薬品工業株式会社 |
アミド化合物
|
|
JP5564045B2
(ja)
|
2008-09-02 |
2014-07-30 |
ノバルティス アーゲー |
二環式キナーゼ阻害剤
|
|
CA2743134A1
(en)
|
2008-11-10 |
2010-05-14 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2010059549A1
(en)
*
|
2008-11-18 |
2010-05-27 |
Glaxosmithkline Llc |
Prolyl hydroxylase inhibitors
|
|
ES2921576T3
(es)
|
2008-12-19 |
2022-08-29 |
Vertex Pharma |
Compuestos útiles como inhibidores de la quinasa ATR
|
|
US8546405B2
(en)
|
2008-12-23 |
2013-10-01 |
Abbott Laboratories |
Anti-viral compounds
|
|
SG172352A1
(en)
|
2008-12-23 |
2011-07-28 |
Abbott Lab |
Anti-viral compounds
|
|
US8741917B2
(en)
|
2009-01-15 |
2014-06-03 |
Rutgers, The State University Of New Jersey |
Benzo [C] phenanthridines as antimicrobial agents
|
|
NZ595674A
(en)
|
2009-04-02 |
2012-12-21 |
Ct Nac Investigaciones Oncologicas Cnio |
Imidazo[2,1-b][1,3,4]thiadiazole derivatives
|
|
US9278922B2
(en)
|
2009-04-15 |
2016-03-08 |
Abbvie Inc. |
Anti-viral compounds
|
|
US20120059026A1
(en)
|
2009-04-30 |
2012-03-08 |
University Of Medicine And Dentistry Of New Jersey |
Antimicrobial agents
|
|
NZ596302A
(en)
|
2009-05-15 |
2014-01-31 |
Novartis Ag |
Aryl pyridine as aldosterone synthase inhibitors
|
|
WO2010135568A1
(en)
|
2009-05-22 |
2010-11-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of mtor and their use to treat cancer
|
|
AU2010265971B2
(en)
*
|
2009-06-25 |
2014-08-14 |
Amgen Inc. |
Heterocyclic compounds and their uses as inhibitors of PI3 K activity
|
|
NZ598220A
(en)
|
2009-08-17 |
2014-02-28 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
|
WO2011021678A1
(ja)
*
|
2009-08-21 |
2011-02-24 |
武田薬品工業株式会社 |
縮合複素環化合物
|
|
EA021113B1
(ru)
*
|
2009-09-03 |
2015-04-30 |
Бристол-Майерс Сквибб Кампани |
Хиназолины в качестве ингибиторов калиевых каналов
|
|
JP2013504325A
(ja)
*
|
2009-09-09 |
2013-02-07 |
アビラ セラピューティクス， インコーポレイテッド |
Ｐｉ３キナーゼインヒビターおよびその使用
|
|
US9556426B2
(en)
|
2009-09-16 |
2017-01-31 |
Celgene Avilomics Research, Inc. |
Protein kinase conjugates and inhibitors
|
|
US20120245180A1
(en)
*
|
2009-09-28 |
2012-09-27 |
Glaxosmithkline Llc |
Combination
|
|
EP2488184A4
(en)
*
|
2009-10-12 |
2013-04-24 |
Glaxosmithkline Llc |
COMBINATION
|
|
WO2011051958A1
(en)
|
2009-10-30 |
2011-05-05 |
E.I. Du Pont De Nemours And Company |
Fungicidal pyrazolones
|
|
JP2013516422A
(ja)
|
2009-12-30 |
2013-05-13 |
アビラ セラピューティクス， インコーポレイテッド |
タンパク質のリガンド−指向性共有的修飾
|
|
US9334244B2
(en)
|
2010-05-12 |
2016-05-10 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8962631B2
(en)
|
2010-05-12 |
2015-02-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
CA2798760A1
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
2-aminopyridine derivatives useful as inhibitors of atr kinase
|
|
US9062008B2
(en)
|
2010-05-12 |
2015-06-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
EP2568984A1
(en)
|
2010-05-12 |
2013-03-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
NZ603477A
(en)
|
2010-05-12 |
2014-09-26 |
Vertex Pharma |
Compounds useful as inhibitors of atr kinase
|
|
WO2011156626A1
(en)
|
2010-06-09 |
2011-12-15 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
MX2013000103A
(es)
|
2010-06-23 |
2013-06-13 |
Vertex Pharma |
Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
|
|
CA2803890A1
(en)
*
|
2010-06-25 |
2011-12-29 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
CA2806332C
(en)
*
|
2010-07-30 |
2017-11-14 |
Oncotherapy Science, Inc. |
Quinoline derivatives and melk inhibitors containing the same
|
|
WO2012021480A1
(en)
*
|
2010-08-09 |
2012-02-16 |
Glaxosmithkline Llc |
Combination
|
|
US20140080810A1
(en)
|
2010-11-15 |
2014-03-20 |
Exelixis, Inc. |
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
|
|
WO2012068106A2
(en)
|
2010-11-15 |
2012-05-24 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
|
JP2013545756A
(ja)
*
|
2010-11-16 |
2013-12-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド |
投与および治療方法
|
|
AU2011329666A1
(en)
*
|
2010-11-19 |
2013-05-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Method of treatment with BRaf inhibitor
|
|
EP2643316A2
(en)
|
2010-11-24 |
2013-10-02 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
US9604963B2
(en)
|
2011-03-04 |
2017-03-28 |
Glaxosmithkline Intellectual Property Development Limited |
Amino-quinolines as kinase inhibitors
|
|
EP2684167B1
(en)
|
2011-03-08 |
2020-09-09 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
|
CN102718745A
(zh)
*
|
2011-03-30 |
2012-10-10 |
中国科学院上海药物研究所 |
新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
|
|
MX2013011450A
(es)
|
2011-04-05 |
2014-02-03 |
Vertex Pharma |
Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
|
|
CN103635183A
(zh)
*
|
2011-04-29 |
2014-03-12 |
埃克塞利希斯股份有限公司 |
使用pi3k/mtor的吡啶并嘧啶抑制剂来治疗淋巴瘤的方法
|
|
EP2723747A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
US8822469B2
(en)
|
2011-06-22 |
2014-09-02 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
|
|
US9309250B2
(en)
|
2011-06-22 |
2016-04-12 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
|
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
|
US8765751B2
(en)
|
2011-09-30 |
2014-07-01 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
WO2013049720A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
CN108685922A
(zh)
|
2011-09-30 |
2018-10-23 |
沃泰克斯药物股份有限公司 |
用atr抑制剂治疗胰腺癌和非小细胞肺癌
|
|
WO2013049722A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
CN106496173A
(zh)
|
2011-09-30 |
2017-03-15 |
沃泰克斯药物股份有限公司 |
用于制备可用作atr激酶抑制剂的化合物的方法
|
|
CN103906735B
(zh)
|
2011-11-04 |
2016-12-07 |
霍夫曼-拉罗奇有限公司 |
新芳基-喹啉衍生物
|
|
US8846918B2
(en)
|
2011-11-09 |
2014-09-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2015502925A
(ja)
|
2011-11-09 |
2015-01-29 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
|
|
US8841337B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8846917B2
(en)
|
2011-11-09 |
2014-09-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8841450B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
EP2790705B1
(en)
|
2011-12-15 |
2017-12-06 |
Novartis AG |
Use of inhibitors of the activity or function of pi3k
|
|
US9822108B2
(en)
|
2012-01-13 |
2017-11-21 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
KR20140127307A
(ko)
*
|
2012-02-06 |
2014-11-03 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
섬유성 질병을 치료하기 위한 pi3k 억제제
|
|
CA2861496A1
(en)
*
|
2012-02-06 |
2013-08-15 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pi3k inhibitors for treating cough
|
|
US9475783B2
(en)
|
2012-03-21 |
2016-10-25 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
CN108478577A
(zh)
|
2012-04-05 |
2018-09-04 |
沃泰克斯药物股份有限公司 |
可用作atr激酶抑制剂的化合物及其组合疗法
|
|
WO2013192423A2
(en)
|
2012-06-20 |
2013-12-27 |
Eutropics Pharmaceuticals, Inc. |
Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
|
|
AR092529A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
|
TW201425307A
(zh)
|
2012-09-13 |
2014-07-01 |
Glaxosmithkline Llc |
作為激酶抑制劑之胺基－喹啉類
|
|
CN103497177B
(zh)
*
|
2012-09-29 |
2017-03-22 |
天津滨江药物研发有限公司 |
作为c‑Met抑制剂的氨基芳香杂环类化合物及其制备方法
|
|
DK2904406T3
(en)
|
2012-10-04 |
2018-06-18 |
Vertex Pharma |
METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
|
|
EP2909202A1
(en)
|
2012-10-16 |
2015-08-26 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
CN103788071A
(zh)
*
|
2012-11-01 |
2014-05-14 |
中国人民解放军第二军医大学 |
N-(5-(喹啉-6-基)吡啶-3-基)苯磺酰胺衍生物、制备方法及治疗用途
|
|
US20160038503A1
(en)
|
2012-11-21 |
2016-02-11 |
David Richard |
Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
|
|
SI2941432T1
(en)
|
2012-12-07 |
2018-07-31 |
Vertex Pharmaceuticals Incorporated |
2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
|
|
CA2902132C
(en)
|
2013-02-21 |
2020-09-22 |
Glaxosmithkline Intellectual Property Development Limited |
Quinazolines as kinase inhibitors
|
|
WO2014143240A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
|
CN104098542A
(zh)
*
|
2013-04-11 |
2014-10-15 |
苏州朗信医药科技有限公司 |
一种6-溴代-4-(4-吡嗪基)喹啉的制备方法
|
|
US10732182B2
(en)
|
2013-08-01 |
2020-08-04 |
Eutropics Pharmaceuticals, Inc. |
Method for predicting cancer sensitivity
|
|
CN104418858B
(zh)
|
2013-08-30 |
2018-12-11 |
浙江医药股份有限公司新昌制药厂 |
2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
|
|
KR20160060100A
(ko)
|
2013-09-22 |
2016-05-27 |
칼리토르 사이언시즈, 엘엘씨 |
치환된 아미노피리미딘 화합물 및 이용 방법
|
|
CN104557955B
(zh)
*
|
2013-10-23 |
2017-05-03 |
上海汇伦生命科技有限公司 |
作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
|
|
JP6538044B2
(ja)
|
2013-10-30 |
2019-07-03 |
ユートロピクス ファーマシューティカルズ， インコーポレイテッド |
化学療法感受性および化学毒性を判定する方法
|
|
US9458150B2
(en)
|
2013-11-08 |
2016-10-04 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
US10233176B2
(en)
*
|
2013-11-27 |
2019-03-19 |
Signalchem Lifesciences Corporation |
Aminopyridine derivatives as TAM family kinase inhibitors
|
|
PT3077397T
(pt)
|
2013-12-06 |
2020-01-22 |
Vertex Pharma |
Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
|
|
WO2015131080A1
(en)
|
2014-02-28 |
2015-09-03 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CN104922116B
(zh)
*
|
2014-03-23 |
2020-08-11 |
上海诗丹德生物技术有限公司 |
甲基丙烯酰基苯并咪唑酮衍生物的用途
|
|
NO2714752T3
(enExample)
*
|
2014-05-08 |
2018-04-21 |
|
|
|
MX373102B
(es)
|
2014-06-05 |
2020-04-17 |
Vertex Pharma |
Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
|
|
SG11201610500WA
(en)
|
2014-06-17 |
2017-01-27 |
Vertex Pharma |
Method for treating cancer using a combination of chk1 and atr inhibitors
|
|
WO2015192761A1
(zh)
|
2014-06-17 |
2015-12-23 |
辰欣药业股份有限公司 |
作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
|
|
CN117088931A
(zh)
|
2014-08-12 |
2023-11-21 |
莫纳什大学 |
定向淋巴的前药
|
|
CN105330699B
(zh)
*
|
2014-08-13 |
2018-12-04 |
山东汇睿迪生物技术有限公司 |
一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
|
|
US10155727B2
(en)
|
2014-08-15 |
2018-12-18 |
Janssen Pharmaceuticals, Inc. |
Pyrazoles
|
|
WO2016025917A1
(en)
|
2014-08-15 |
2016-02-18 |
Janssen Pharmaceuticals, Inc. |
Triazoles as nr2b receptor inhibitors
|
|
CN107148425B
(zh)
|
2014-10-29 |
2021-08-03 |
拜斯科阿迪有限公司 |
对mt1-mmp特异性的双环肽配体
|
|
TWI788655B
(zh)
|
2015-02-27 |
2023-01-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
|
FR3033499A1
(fr)
|
2015-03-11 |
2016-09-16 |
Centre Leon-Berard |
Composition pour le traitement des tumeurs neuroendocrines pancreatiques
|
|
CN104961725B
(zh)
*
|
2015-06-18 |
2017-04-19 |
浙江大学 |
4‑α,β不饱和酰胺基喹啉类化合物及制备和应用
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
AU2016291158B2
(en)
|
2015-07-09 |
2020-04-30 |
Janssen Pharmaceutica Nv |
Substituted 4-azaindoles and their use as GluN2B receptor modulators
|
|
CN108137514A
(zh)
*
|
2015-07-30 |
2018-06-08 |
百时美施贵宝公司 |
芳基取代的二环杂芳基化合物
|
|
US10329257B2
(en)
|
2015-08-13 |
2019-06-25 |
The Broad Institute, Inc. |
Compositions and methods for treating tuberculosis
|
|
TWI707852B
(zh)
|
2015-09-02 |
2020-10-21 |
美商林伯士拉克許米公司 |
Tyk2 抑制劑及其用途
|
|
US11738087B2
(en)
|
2015-09-08 |
2023-08-29 |
Monash University |
Lymph directing prodrugs
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
|
AU2016331955B2
(en)
|
2015-09-30 |
2022-07-21 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
|
|
AU2016342027B2
(en)
|
2015-10-23 |
2021-05-13 |
Navitor Pharmaceuticals, Inc. |
Modulators of Sestrin-GATOR2 interaction and uses thereof
|
|
EP3389664A4
(en)
|
2015-12-14 |
2020-01-08 |
Raze Therapeutics Inc. |
MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
|
|
WO2017101829A1
(zh)
*
|
2015-12-16 |
2017-06-22 |
辰欣药业股份有限公司 |
吡啶并[1,2-a]嘧啶酮类似物的晶型及其制备方法和中间体
|
|
US10071988B2
(en)
|
2016-02-10 |
2018-09-11 |
Janssen Pharmaceutica Nv |
Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
|
|
WO2017147316A1
(en)
|
2016-02-25 |
2017-08-31 |
Taxis Pharmaceuticals, Inc. |
Synthetic processes and intermediates
|
|
DK3426243T3
(da)
|
2016-03-09 |
2021-07-19 |
Raze Therapeutics Inc |
3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
|
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
CA3019394A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
ES2870920T3
(es)
|
2016-06-21 |
2021-10-28 |
X4 Pharmaceuticals Inc |
Inhibidores de CXCR4 y usos de los mismos
|
|
EP3472129A4
(en)
|
2016-06-21 |
2019-12-04 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
|
CN109640988A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
|
US10154992B2
(en)
*
|
2016-07-12 |
2018-12-18 |
The Regents Of The University Of California |
Compounds and methods for treating HIV infection
|
|
CN109641892B
(zh)
*
|
2016-08-16 |
2021-07-02 |
默克专利有限公司 |
用作可逆btk抑制剂的2-氧代-咪唑并吡啶及其用途
|
|
TW201819376A
(zh)
|
2016-10-06 |
2018-06-01 |
比利時商健生藥品公司 |
經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
|
|
US10323036B2
(en)
|
2016-10-14 |
2019-06-18 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
|
EP3528816A4
(en)
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
|
CN106580986B
(zh)
*
|
2016-11-28 |
2017-09-15 |
王保亮 |
一种治疗少弱精子症的药物组合物
|
|
CA3043768A1
(en)
|
2016-11-29 |
2018-06-07 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
US20180153922A1
(en)
|
2016-12-06 |
2018-06-07 |
New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery |
Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
|
|
WO2018115203A1
(en)
|
2016-12-23 |
2018-06-28 |
Bicyclerd Limited |
Peptide derivatives having novel linkage structures
|
|
CA3174865A1
(en)
*
|
2016-12-26 |
2018-07-05 |
Institute Of Materia Medica, Chinese Academy Of Medical Sciences |
Quinazoline compound and preparation method, application, and pharmaceutical composition thereof
|
|
US10624968B2
(en)
|
2017-01-06 |
2020-04-21 |
Bicyclerd Limited |
Compounds for treating cancer
|
|
TW202515876A
(zh)
|
2017-03-08 |
2025-04-16 |
日商武田藥品工業股份有限公司 |
Tyk2抑制劑及其用途
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
US10774093B2
(en)
|
2017-03-30 |
2020-09-15 |
Taxis Pharmaceuticals, Inc. |
Synthetic processes and synthetic intermediates
|
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
PL3615019T3
(pl)
|
2017-04-26 |
2026-01-19 |
Navitor Pharmaceuticals, Inc. |
Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie
|
|
US10857196B2
(en)
|
2017-04-27 |
2020-12-08 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
CN110914265B
(zh)
*
|
2017-05-15 |
2022-12-23 |
密歇根大学董事会 |
作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物
|
|
EP3645549A1
(en)
|
2017-06-26 |
2020-05-06 |
BicycleRD Limited |
Bicyclic peptide ligands with detectable moieties and uses thereof
|
|
SI3658557T1
(sl)
|
2017-07-28 |
2024-10-30 |
Takeda Pharmaceutical Company Limited |
Zaviralci TYK2 in njihova uporaba
|
|
JP7670481B2
(ja)
|
2017-08-04 |
2025-04-30 |
バイスクルテクス・リミテッド |
Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
|
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
CA3077739A1
(en)
|
2017-08-29 |
2019-03-07 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
CN107793404A
(zh)
*
|
2017-11-07 |
2018-03-13 |
全椒先奇医药科技有限公司 |
一种治疗缺血性脑损伤药物组合物及其应用
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
BR112020015396A2
(pt)
|
2018-01-29 |
2020-12-08 |
Merck Patent Gmbh |
Inididores de gcn2 e usos dos mesmos
|
|
JP7229257B2
(ja)
|
2018-01-29 |
2023-02-28 |
メルク パテント ゲーエムベーハー |
Ｇｃｎ２阻害剤およびその使用
|
|
CN111902429A
(zh)
|
2018-02-23 |
2020-11-06 |
拜斯科技术开发有限公司 |
多聚体双环肽配体
|
|
EP3759086A1
(en)
|
2018-02-27 |
2021-01-06 |
Artax Biopharma Inc. |
Chromene derivatives as inhibitors of tcr-nck interaction
|
|
BR112020018094A2
(pt)
*
|
2018-03-08 |
2020-12-22 |
Incyte Corporation |
Compostos de aminopirazina diol como inibidores de pi3k-¿
|
|
WO2019193516A2
(en)
|
2018-04-04 |
2019-10-10 |
Janssen Pharmaceutica Nv |
Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
|
|
ES2969982T3
(es)
|
2018-04-24 |
2024-05-23 |
Vertex Pharma |
Compuestos de pteridinona y usos de los mismos
|
|
HRP20241163T1
(hr)
|
2018-04-24 |
2024-11-22 |
Merck Patent Gmbh |
Antiproliferacijski spojevi i njihova uporaba
|
|
EP3807248A4
(en)
*
|
2018-05-29 |
2021-10-27 |
Council of Scientific and Industrial Research |
BICYCLIC TOPOISOMERASE I INHIBITOR COMPOUNDS, THEIR PREPARATION AND USE
|
|
EP3575305A1
(fr)
*
|
2018-05-31 |
2019-12-04 |
Biocidal Alternative Solutions |
Procédé de fabrication de composés comprenant un groupe fonctionnel oxazolopyridinones
|
|
CA3102279A1
(en)
|
2018-06-01 |
2019-12-05 |
Cornell University |
Combination therapy for pi3k-associated disease or disorder
|
|
WO2019241789A1
(en)
|
2018-06-15 |
2019-12-19 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
KR102595520B1
(ko)
*
|
2018-07-05 |
2023-10-30 |
엘지디스플레이 주식회사 |
헤테로아릴기를 가진 벤즈아졸 유도체 및 이를 포함하는 유기전계발광소자
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
WO2020051424A1
(en)
|
2018-09-07 |
2020-03-12 |
Pic Therapeutics |
Eif4e inhibitors and uses thereof
|
|
CN113271940A
(zh)
|
2018-10-15 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
|
WO2020084305A1
(en)
|
2018-10-23 |
2020-04-30 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
EP3870158A4
(en)
|
2018-10-24 |
2022-08-10 |
Navitor Pharmaceuticals, Inc. |
Polymorphic compounds and uses thereof
|
|
CA3120866A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CA3119773A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
WO2020128527A1
(en)
|
2018-12-21 |
2020-06-25 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
US12492224B2
(en)
|
2018-12-21 |
2025-12-09 |
Bicycletx Limited |
Bicyclic peptide ligands specific for PD-L1
|
|
CN113348021B
(zh)
|
2019-01-23 |
2025-07-11 |
武田药品工业株式会社 |
Tyk2抑制剂和其用途
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
SG11202110828UA
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Ltd |
Bicycle toxin conjugates and uses thereof
|
|
CN120574283A
(zh)
|
2019-04-05 |
2025-09-02 |
凯麦拉医疗公司 |
Stat降解剂和其用途
|
|
US12304899B2
(en)
|
2019-05-30 |
2025-05-20 |
Merck Sharp & Dohme Llc |
Factor XI activation inhibitors
|
|
CA3141826A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
JP7667097B2
(ja)
|
2019-06-14 |
2025-04-22 |
ヤンセン ファーマシューティカ エヌ．ベー． |
置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
|
|
MX2021015511A
(es)
|
2019-06-14 |
2022-01-31 |
Janssen Pharmaceutica Nv |
Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
|
|
BR112021025141A2
(pt)
|
2019-06-14 |
2022-01-25 |
Janssen Pharmaceutica Nv |
Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
|
|
TW202112774A
(zh)
|
2019-06-14 |
2021-04-01 |
比利時商健生藥品公司 |
經取代之吡唑并－吡啶醯胺及其作為ｇｌｕｎ２ｂ受體調節劑之用途
|
|
CA3143103A1
(en)
|
2019-06-14 |
2020-12-17 |
Janssen Pharmaceutica Nv |
Pyridine carbamates and their use as glun2b receptor modulators
|
|
CN114008052A
(zh)
|
2019-06-14 |
2022-02-01 |
詹森药业有限公司 |
取代的吡唑并-吡嗪以及它们作为GluN2B受体调节剂的用途
|
|
AU2020293642A1
(en)
|
2019-06-14 |
2022-01-20 |
Janssen Pharmaceutica Nv |
Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
US11845724B2
(en)
|
2019-09-11 |
2023-12-19 |
Vincere Biosciences, Inc. |
USP30 inhibitors and uses thereof
|
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
|
US11723890B2
(en)
|
2019-11-01 |
2023-08-15 |
Navitor Pharmaceuticals, Inc. |
Methods of treatment using an mTORC1 modulator
|
|
AU2020397938A1
(en)
|
2019-12-05 |
2022-06-23 |
Janssen Pharmaceutica Nv |
Rapamycin analogs and uses thereof
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
EP4081308A4
(en)
|
2019-12-23 |
2024-01-24 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
IL295362A
(en)
|
2020-02-05 |
2022-10-01 |
Puretech Lyt Inc |
Lipid drug inhibitors of neurosteroids
|
|
TW202146393A
(zh)
|
2020-03-03 |
2021-12-16 |
美商皮克醫療公司 |
Eif4e抑制劑及其用途
|
|
KR20230005160A
(ko)
|
2020-03-19 |
2023-01-09 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Mdm2 분해제 및 이의 용도
|
|
TWI904146B
(zh)
*
|
2020-03-31 |
2025-11-11 |
美商卡默森屈有限公司 |
使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
US20230250110A1
(en)
|
2020-06-03 |
2023-08-10 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
AU2021322934A1
(en)
|
2020-08-03 |
2023-03-30 |
Bicycletx Limited |
Peptide-based linkers
|
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
US12331046B2
(en)
|
2020-10-23 |
2025-06-17 |
Nimbus Clotho, Inc. |
CTPS1 inhibitors and uses thereof
|
|
CA3200814A1
(en)
|
2020-12-02 |
2022-06-09 |
Alfredo C. Castro |
Tead inhibitors and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4259144A4
(en)
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
CN116867758A
(zh)
|
2020-12-30 |
2023-10-10 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
US12378229B2
(en)
|
2021-02-02 |
2025-08-05 |
Liminal Biosciences Limited |
GPR84 antagonists and uses thereof
|
|
MX2023009060A
(es)
|
2021-02-02 |
2023-09-29 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
|
EP4291235A4
(en)
|
2021-02-12 |
2025-01-08 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND USES THEREOF
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
US12171768B2
(en)
|
2021-02-15 |
2024-12-24 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
US20240156805A1
(en)
|
2021-02-16 |
2024-05-16 |
Ribotech Co., Ltd. |
Compound for inhibiting nonsense-mediated mrna decay
|
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
KR20230158659A
(ko)
*
|
2021-03-18 |
2023-11-21 |
쑤저우 궈쾅 팜테크 코포레이션 리미티드 |
Ctla-4 소분자 분해제 및 그 응용
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
US12325697B2
(en)
|
2021-04-09 |
2025-06-10 |
Nimbus Clio, Inc. |
CBL-B modulators and uses thereof
|
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
KR20240020735A
(ko)
|
2021-05-07 |
2024-02-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Cdk2 분해제 및 그 용도
|
|
CN115353512B
(zh)
*
|
2021-07-30 |
2025-07-08 |
上海翊石医药科技有限公司 |
一种杂环脲类化合物及其制备方法和用途
|
|
CN113416181B
(zh)
*
|
2021-08-02 |
2022-05-03 |
四川大学 |
喹唑啉类衍生物及其用途
|
|
CA3229560A1
(en)
|
2021-08-25 |
2023-03-02 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
CN115869320A
(zh)
*
|
2021-09-27 |
2023-03-31 |
广州嘉越医药科技有限公司 |
一种吡啶并[1,2-a]嘧啶酮类化合物的应用
|
|
CA3236265A1
(en)
|
2021-10-29 |
2023-05-04 |
William Leong |
Irak4 degraders and synthesis thereof
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
CA3243560A1
(en)
|
2022-01-31 |
2023-08-03 |
Kymera Therapeutics, Inc. |
Iraqi Degradation Agents and Their Uses
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
US11878958B2
(en)
|
2022-05-25 |
2024-01-23 |
Ikena Oncology, Inc. |
MEK inhibitors and uses thereof
|
|
WO2024012534A1
(zh)
*
|
2022-07-13 |
2024-01-18 |
武汉人福创新药物研发中心有限公司 |
杂环并苯环类化合物及其制备方法和用途
|
|
IL318577A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES
|
|
KR20250056924A
(ko)
|
2022-08-02 |
2025-04-28 |
리미널 바이오사이언시스 리미티드 |
치환된 피리돈 gpr84 길항제 및 이의 용도
|
|
US20260028330A1
(en)
|
2022-08-02 |
2026-01-29 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
EP4605089A1
(en)
*
|
2022-10-20 |
2025-08-27 |
Mekanistic Therapeutics LLC |
Compounds useful in modulating egfr and pi3k
|
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
CN116239594B
(zh)
*
|
2023-03-05 |
2023-09-22 |
贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) |
6-(咪唑并[1,2-a]吡啶-6-基)喹唑啉衍生物及用途
|
|
AU2024312190A1
(en)
|
2023-06-23 |
2025-07-03 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2025045915A1
(en)
*
|
2023-08-29 |
2025-03-06 |
Institut National de la Santé et de la Recherche Médicale |
Methods for inducing muscle hypertrophy
|
|
AU2024344754A1
(en)
|
2023-09-21 |
2026-04-02 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|
|
CN118126038B
(zh)
*
|
2024-05-08 |
2024-07-12 |
烟台大学 |
吡唑并吡啶类衍生物及其制备方法和应用
|